These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 1387255)
1. Treatment of autoimmune diseases with intravenous gammaglobulin. Gelfand EW Semin Hematol; 1992 Jul; 29(3 Suppl 2):127-33. PubMed ID: 1387255 [No Abstract] [Full Text] [Related]
2. T cell tolerance: models for clinical application to allergy and autoimmunity. Schad VC Chem Immunol; 1994; 58():193-205. PubMed ID: 8011152 [No Abstract] [Full Text] [Related]
3. Autoimmunity following neonatal tolerance to alloantigens: role of donor I-A and I-E molecules. Kramar G; Schurmans S; Berney M; Izui S; del Giudice G; Lambert PH J Autoimmun; 1995 Apr; 8(2):177-92. PubMed ID: 7612147 [TBL] [Abstract][Full Text] [Related]
4. Transient T and B cell activation after neonatal induction of tolerance to MHC class II or Mls alloantigens. Schurmans S; Brighouse G; Kramer G; Wen L; Izui S; Merino J; Lambert PH J Immunol; 1991 Apr; 146(7):2152-60. PubMed ID: 1672344 [TBL] [Abstract][Full Text] [Related]
5. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. Kazatchkine MD; Kaveri SV N Engl J Med; 2001 Sep; 345(10):747-55. PubMed ID: 11547745 [No Abstract] [Full Text] [Related]
7. [Intravenous immunoglobulins (IgIV) in the treatment of autoimmune diseases and systemic inflammatory diseases]. Kazatchkine M Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):209-10. PubMed ID: 8337128 [No Abstract] [Full Text] [Related]
8. T-splenocytes from non-obese diabetic mice binding to xenogeneic pancreatic beta-cells in vitro. Implication of the alpha/beta T-cell receptor and of major histocompatibility complex class II molecules from target cells. Martignat L; Feve B; Ouary M; Pogu S; Charbonnel B; Saï P J Autoimmun; 1993 Dec; 6(6):753-69. PubMed ID: 8155255 [TBL] [Abstract][Full Text] [Related]
9. [A change in the expression of histocompatibility antigens could lead to autoimmunity]. Pujol-Borrell R; Bottazzo GF; Feldmann M Med Clin (Barc); 1984 Apr; 82(13):594-5. PubMed ID: 6610082 [No Abstract] [Full Text] [Related]
17. Development of antigen-specific therapies for autoimmune disease. Steinman L Mol Biol Med; 1990 Aug; 7(4):333-9. PubMed ID: 2233245 [TBL] [Abstract][Full Text] [Related]
18. Tolerogenic dendritic cells for autoimmune disease and transplantation. Thomson AW; Robbins PD Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii90-6. PubMed ID: 19022823 [TBL] [Abstract][Full Text] [Related]
19. Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases. Fowler E; Weiner HL Biopolymers; 1997; 43(4):323-35. PubMed ID: 9316395 [TBL] [Abstract][Full Text] [Related]
20. The immune system and intravenous administration of immune globulin. Part I, The immune system. Frey AM J Intraven Nurs; 1991; 14(5):315-30. PubMed ID: 1748915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]